Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1995 Aug;69(8):4957–4962. doi: 10.1128/jvi.69.8.4957-4962.1995

Cross-protection of mice against a global spectrum of rabies virus variants.

D L Lodmell 1, J S Smith 1, J J Esposito 1, L C Ewalt 1
PMCID: PMC189311  PMID: 7609065

Abstract

Rabies, a continuing worldwide problem, kills tens of thousands of people and millions of animals each year. The problem is most severe in developing countries, where cell culture-derived vaccines are unaffordable and the available nervous tissue-derived vaccines are often of questionable immunogenicity and may produce neurological complications. To determine the feasibility of developing a vaccine with worldwide applicability, we investigated whether recombinant vaccinia viruses expressing either the glycoprotein (G), the nucleoprotein (N), or both the G and N (GN) of the challenge virus strain (CVS) of rabies virus would cross-protect mice against 17 rabies virus isolates representing the spectrum of rabies virus variants found worldwide. The results were compared with the commercially available human diploid cell vaccine (HDCV). Among mice injected with any of the 17 viruses, > or = 95% were protected by vaccination with recombinant viruses expressing G or GN, and > or = 85% of the mice were protected by the HDCV. The recombinant virus expressing N was less protective, protecting against only 11 of the 17 viruses. Antibody prepared against the G of the strains used in the vaccines neutralized all 17 viruses, and sera from mice infected with any one virus variant cross-neutralized all of the other viruses. Thus, no antigenic differences that would potentiate vaccine failures were identified. These studies suggest that a single rabies virus strain or its G would protect globally against wild-type rabies viruses.

Full Text

The Full Text of this article is available as a PDF (365.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Artois M., Guittré C., Thomas I., Leblois H., Brochier B., Barrat J. Potential pathogenicity for rodents of vaccines intended for oral vaccination against rabies: a comparison. Vaccine. 1992;10(8):524–528. doi: 10.1016/0264-410x(92)90351-j. [DOI] [PubMed] [Google Scholar]
  2. Arya S. C. Spread of 'unconventional viruses' through sheep-brain rabies vaccines. Vaccine. 1991 Jan;9(1):70–70. doi: 10.1016/0264-410x(91)90332-z. [DOI] [PubMed] [Google Scholar]
  3. Brochier B., Thomas I., Bauduin B., Leveau T., Pastoret P. P., Languet B., Chappuis G., Desmettre P., Blancou J., Artois M. Use of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies. Vaccine. 1990 Apr;8(2):101–104. doi: 10.1016/0264-410x(90)90129-a. [DOI] [PubMed] [Google Scholar]
  4. Burrows R. Rabies in wild dogs. Nature. 1992 Sep 24;359(6393):277–277. doi: 10.1038/359277a0. [DOI] [PubMed] [Google Scholar]
  5. Bögel K., Motschwiller E. Incidence of rabies and post-exposure treatment in developing countries. Bull World Health Organ. 1986;64(6):883–887. [PMC free article] [PubMed] [Google Scholar]
  6. Charlton K. M., Artois M., Prevec L., Campbell J. B., Casey G. A., Wandeler A. I., Armstrong J. Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Arch Virol. 1992;123(1-2):169–179. doi: 10.1007/BF01317147. [DOI] [PubMed] [Google Scholar]
  7. Charlton K. M., Casey G. A., Boucher D. W., Wiktor T. J. Antigenic variants of rabies virus. Comp Immunol Microbiol Infect Dis. 1982;5(1-3):113–115. doi: 10.1016/0147-9571(82)90023-6. [DOI] [PubMed] [Google Scholar]
  8. Clark H. F. Rabies viruses increase in virulence when propagated in neuroblastoma cell culture. Science. 1978 Mar 10;199(4333):1072–1075. doi: 10.1126/science.628831. [DOI] [PubMed] [Google Scholar]
  9. Esposito J. J., Knight J. C., Shaddock J. H., Novembre F. J., Baer G. M. Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology. 1988 Jul;165(1):313–316. doi: 10.1016/0042-6822(88)90692-7. [DOI] [PubMed] [Google Scholar]
  10. Esposito J., Brechling K., Baer G., Moss B. Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies. Virus Genes. 1987 Nov;1(1):7–21. doi: 10.1007/BF00125682. [DOI] [PubMed] [Google Scholar]
  11. Fishbein D. B., Robinson L. E. Rabies. N Engl J Med. 1993 Nov 25;329(22):1632–1638. doi: 10.1056/NEJM199311253292208. [DOI] [PubMed] [Google Scholar]
  12. Fu Z. F., Dietzschold B., Schumacher C. L., Wunner W. H., Ertl H. C., Koprowski H. Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):2001–2005. doi: 10.1073/pnas.88.5.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lafay F., Bénéjean J., Tuffereau C., Flamand A., Coulon P. Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SADBern. Vaccine. 1994 Mar;12(4):317–320. doi: 10.1016/0264-410x(94)90095-7. [DOI] [PubMed] [Google Scholar]
  14. Lafon M., Lafage M., Martinez-Arends A., Ramirez R., Vuillier F., Charron D., Lotteau V., Scott-Algara D. Evidence for a viral superantigen in humans. Nature. 1992 Aug 6;358(6386):507–510. doi: 10.1038/358507a0. [DOI] [PubMed] [Google Scholar]
  15. Lafon M., Scott-Algara D., Marche P. N., Cazenave P. A., Jouvin-Marche E. Neonatal deletion and selective expansion of mouse T cells by exposure to rabies virus nucleocapsid superantigen. J Exp Med. 1994 Oct 1;180(4):1207–1215. doi: 10.1084/jem.180.4.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lafon M., Wiktor T. J., Macfarlan R. I. Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J Gen Virol. 1983 Apr;64(Pt 4):843–851. doi: 10.1099/0022-1317-64-4-843. [DOI] [PubMed] [Google Scholar]
  17. Lodmell D. L., Esposito J. J., Ewalt L. C. Rabies virus antinucleoprotein antibody protects against rabies virus challenge in vivo and inhibits rabies virus replication in vitro. J Virol. 1993 Oct;67(10):6080–6086. doi: 10.1128/jvi.67.10.6080-6086.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lodmell D. L., Ewalt L. C. Immune sera and antiglycoprotein monoclonal antibodies inhibit in vitro cell-to-cell spread of pathogenic rabies viruses. J Virol. 1987 Oct;61(10):3314–3318. doi: 10.1128/jvi.61.10.3314-3318.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lodmell D. L., Sumner J. W., Esposito J. J., Bellini W. J., Ewalt L. C. Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection. J Virol. 1991 Jun;65(6):3400–3405. doi: 10.1128/jvi.65.6.3400-3405.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Morrison H. G., Goldsmith C. S., Regnery H. L., Auperin D. D. Simultaneous expression of the Lassa virus N and GPC genes from a single recombinant vaccinia virus. Virus Res. 1991 Mar;18(2-3):231–241. doi: 10.1016/0168-1702(91)90021-m. [DOI] [PubMed] [Google Scholar]
  21. Nicholson K. G. Modern vaccines. Rabies. Lancet. 1990 May 19;335(8699):1201–1205. doi: 10.1016/0140-6736(90)92710-y. [DOI] [PubMed] [Google Scholar]
  22. Petricciani J. C. Ongoing tragedy of rabies. Lancet. 1993 Oct 30;342(8879):1067–1068. doi: 10.1016/0140-6736(93)92058-2. [DOI] [PubMed] [Google Scholar]
  23. Prabhakar B. S., Parks N. F., Clark H. F. Altered expression of rabies virus antigenic determinants associated with chronic infection and virulence. J Gen Virol. 1983 Jan;64(Pt 1):251–254. doi: 10.1099/0022-1317-64-1-251. [DOI] [PubMed] [Google Scholar]
  24. Rhim J. S., Cho H. Y., Huebner R. J. Non-producer human cells induced by murine sarcoma virus. Int J Cancer. 1975 Jan 15;15(1):23–29. doi: 10.1002/ijc.2910150104. [DOI] [PubMed] [Google Scholar]
  25. Schneider L. G. Antigenic variants of rabies virus. Comp Immunol Microbiol Infect Dis. 1982;5(1-3):101–107. doi: 10.1016/0147-9571(82)90021-2. [DOI] [PubMed] [Google Scholar]
  26. Smith J. S., Fishbein D. B., Rupprecht C. E., Clark K. Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med. 1991 Jan 24;324(4):205–211. doi: 10.1056/NEJM199101243240401. [DOI] [PubMed] [Google Scholar]
  27. Smith J. S., Orciari L. A., Yager P. A., Seidel H. D., Warner C. K. Epidemiologic and historical relationships among 87 rabies virus isolates as determined by limited sequence analysis. J Infect Dis. 1992 Aug;166(2):296–307. doi: 10.1093/infdis/166.2.296. [DOI] [PubMed] [Google Scholar]
  28. Smith J. S., Reid-Sanden F. L., Roumillat L. F., Trimarchi C., Clark K., Baer G. M., Winkler W. G. Demonstration of antigenic variation among rabies virus isolates by using monoclonal antibodies to nucleocapsid proteins. J Clin Microbiol. 1986 Oct;24(4):573–580. doi: 10.1128/jcm.24.4.573-580.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Smith J. S., Seidel H. D. Rabies: a new look at an old disease. Prog Med Virol. 1993;40:82–106. [PubMed] [Google Scholar]
  30. Smith J. S., Yager P. A., Baer G. M. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ. 1973 May;48(5):535–541. [PMC free article] [PubMed] [Google Scholar]
  31. Sumner J. W., Fekadu M., Shaddock J. H., Esposito J. J., Bellini W. J. Protection of mice with vaccinia virus recombinants that express the rabies nucleoprotein. Virology. 1991 Aug;183(2):703–710. doi: 10.1016/0042-6822(91)90999-r. [DOI] [PubMed] [Google Scholar]
  32. Sureau P. Contribution to rabies prevention. Vaccine. 1992;10(13):896–899. doi: 10.1016/0264-410x(92)90320-j. [DOI] [PubMed] [Google Scholar]
  33. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine. 1988 Dec;6(6):497–503. doi: 10.1016/0264-410x(88)90100-4. [DOI] [PubMed] [Google Scholar]
  34. Thomas I., Brochier B., Languet B., Blancou J., Peharpre D., Kieny M. P., Desmettre P., Chappuis G., Pastoret P. P. Primary multiplication site of the vaccinia-rabies glycoprotein recombinant virus administered to foxes by the oral route. J Gen Virol. 1990 Jan;71(Pt 1):37–42. doi: 10.1099/0022-1317-71-1-37. [DOI] [PubMed] [Google Scholar]
  35. Wiktor T. J., Koprowski H. Antigenic variants of rabies virus. J Exp Med. 1980 Jul 1;152(1):99–112. doi: 10.1084/jem.152.1.99. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES